PCVX ▲ +10.4% - Vaxcyte, Inc.
$PCVX - Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
05-OCT-2026 06:00 AM ET
Share this post
More filings for $PCVX
PCVX ▲ +0.7% - Vaxcyte, Inc.Oct 4, 2026PCVX ▼ -1.9% - Vaxcyte, Inc.Sep 3, 2026PCVX ▲ +0.1% - Vaxcyte, Inc.Aug 27, 2026PCVX - Vaxcyte, Inc. - SEC Filing Update (11-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 11, 2026PCVX - Vaxcyte, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026PCVX - Vaxcyte, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $PCVX filing history →💬 Comments
Loading comments…
Leave a comment